Indietro

Selezionare la regione

Azienda

Richiedi un consulto sulle cellule staminali

Per saperne di più

I nostri
trapianti

Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:

Immagine
Elenco degli utilizzi delle cellule staminali approvati dai laboratori del gruppo FamiCord:
Nr. Fonte Tipo di fonte Diagnosi Settore medico Anno di applicazione Terapia Paese Età del destinatario
1801 Apheresis Allogeneic Hodgkin Disease Hematology 2024 Standard Therapy Poland 28
1802 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 23
1803 Apheresis Allogeneic Hypoplastic Myelodysplastic Syndrome/Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 71
1804 Apheresis Allogeneic Infant Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 41
1805 Apheresis Allogeneic Kutanes T-Zell-Lymphom, Mycosis Fungoides Hematology 2024 Standard Therapy Poland 72
1806 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 51
1807 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 64
1808 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 66
1809 Apheresis Autologous Mantle Cell Lymphoma Hematology 2024 Standard Therapy Germany 52
1810 Apheresis Autologous Morbus Hodgkin Hematology 2024 Standard Therapy Germany 63
1811 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Poland 43
1812 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 52
1813 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 54
1814 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 60
1815 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 61
1816 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
1817 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
1818 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
1819 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
1820 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 63
1821 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 64
1822 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 65
1823 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 65
1824 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 66
1825 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 66
1826 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 67
1827 Apheresis Allogeneic Multiple Myeloma Hematology 2024 Standard Therapy Germany 68
1828 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 69
1829 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 70
1830 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 71
1831 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 72
1832 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 66
1833 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
1834 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 58
1835 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 61
1836 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 61
1837 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 62
1838 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 70
1839 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 74
1840 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 58
1841 Apheresis Autologous Multiple Myeloma Hematology 2024 Standard Therapy Germany 63
1842 Apheresis Allogeneic Myelodysplastic Hematology 2024 Standard Therapy Poland 68
1843 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 20
1844 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 22
1845 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 54
1846 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 58
1847 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 60
1848 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 62
1849 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 65
1850 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
1851 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
1852 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
1853 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 69
1854 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 69
1855 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 70
1856 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 71
1857 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 73
1858 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Germany 60
1859 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 53
1860 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 69
1861 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 59
1862 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 60
1863 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 49
1864 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 52
1865 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 63
1866 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 66
1867 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 58
1868 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 67
1869 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 65
1870 Apheresis Allogeneic Myelodysplastic Syndrome + Myeloma Hematology 2024 Standard Therapy Germany 67
1871 Apheresis Allogeneic Myelofibrosis Hematology 2024 Standard Therapy Poland 40
1872 Apheresis Allogeneic Myelofibrosis Hematology 2024 Standard Therapy Poland 58
1873 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2024 Standard Therapy Poland 60
1874 Apheresis Allogeneic Myelofibrosis Post. Polycythemia Vera Hematology 2024 Standard Therapy Poland 66
1875 Apheresis Allogeneic Myelofibrosis With Myeloid Metaplasia Hematology 2024 Standard Therapy Poland 67
1876 Apheresis Allogeneic Myeloma Hematology 2024 Standard Therapy Germany 65
1877 Apheresis Allogeneic Myeloproliferative Neoplasms  Hematology 2024 Standard Therapy Poland 74
1878 Apheresis Allogeneic Myeloproliferative Neoplasms/Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 68
1879 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 23
1880 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 50
1881 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 50
1882 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 67
1883 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 46
1884 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Poland 65
1885 Apheresis Autologous Non-Hodgkin Lymphoma Hematology 2024 Standard Therapy Germany 66
1886 Apheresis Autologous Non-Hodgkin Lymphoma – relapse Hematology 2024 Standard Therapy Germany 54
1887 Apheresis Autologous Nonseminoma Hematology 2024 Standard Therapy Germany 38
1888 Apheresis Allogeneic Osteomyelitis Hematology 2024 Standard Therapy Poland 65
1889 Apheresis Allogeneic Post-Et-Myelofibrosis Hematology 2024 Standard Therapy Poland 59
1890 Apheresis Allogeneic Post-Pv-Myelofibrosis Hematology 2024 Standard Therapy Poland 64
1891 Apheresis Autologous Primary Central Nervous System Lymphoma Hematology 2024 Standard Therapy Germany 60
1892 Apheresis Allogeneic Primary Myelofibrosis Hematology 2024 Standard Therapy Poland 52
1893 Apheresis Allogeneic Primary Myelofibrosis Hematology 2024 Standard Therapy Poland 67
1894 Apheresis Allogeneic Primary Myelofibrosis Hematology 2024 Standard Therapy Poland 70
1895 Apheresis Allogeneic Relapsed B-Cell Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 12
1896 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 15
1897 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 10
1898 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 60
1899 Apheresis Allogeneic Severe Aplastic Anemia Progressed To Myelodysplastic Syndrome Hematology 2024 Standard Therapy Poland 21
1900 Apheresis Autologous Multiple myeloma Hematology 2024 Standard Therapy Germany 63